Medical Research Council (MRC)
UKRI Translation Impact Acceleration Accounts 2027 – MRC
4:00pm UK time
Last verified:
The UKRI Translation Impact Acceleration Accounts 2027 funds UK research organisations to translate biomedical discoveries toward clinical and commercial impact, with budgets of £150,000-£750,000 per year over three years. The scheme targets teams ready to move research out of the lab into healthcare practice, industry partnerships, or licensing opportunities, with at least half the project spending on MRC-remit research. Consortia across multiple institutions are welcome where scientifically justified, and the scheme explicitly supports engagement and training activities (capped at 15% of spend).
Details
| Funder | Medical Research Council (MRC) |
| Budget | £150,000–£750,000 per year |
| Deadline | 15 September 2026 |
| Duration | 3 years |
| Consortium | Consortia permitted — lead institution plus collaborating institutions listed as project co-leads; scientific justification required |
| Application | Single stage |
| Eligible countries | GB |
Eligibility & scope
Open competition for UK research organisations in MRC remit. Consortia or joint applications from groups of institutions are welcomed where scientifically justified. At least 50% of activities must be within MRC remit. Engagement/training activities capped at 15% of budget. Submitted via UKRI Funding Service.
Who Should Apply
- •UK-based research organisations in the MRC remit (biomedical and life sciences)
- •Teams with early-stage research ready to move toward clinical or commercial application
- •Consortium leads from multiple institutions working on a shared translational challenge
- •Groups planning structured engagement with industry partners, NHS trusts, or regulatory pathways
- •Researchers willing to allocate up to 15% of budget to training and knowledge-exchange activities
Key Dates
- •Deadline 15 September 2026 at 4:00pm UK time
- •Single-stage application
- •Three-year project duration
Tips for Applicants
- ✓Use the consortium structure if you have multi-site validation or clinical delivery plans; justify the lead + co-lead arrangement clearly, as reviewers screen for genuine collaboration over administrative fragmentation.
- ✓Front-load evidence of clinical or commercial route-to-market: letters of support from NHS services, industry partners, or regulatory advisors carry weight here more than in basic-research panels.
- ✓Keep engagement and training spend visible and purposeful, the 15% cap is enforced, but reviewers reward spending on skills that unblock translation (e.g. GCP training for clinical trials, IP management for spin-outs) over generic dissemination.
Frequently Asked Questions
How much funding does the UKRI Translation Impact Acceleration Accounts 2027 provide?
Between £150,000 and £750,000 per year for a three-year project; total budgets therefore range from £450,000 to £2.25 million.
Who is eligible for the UKRI Translation Impact Acceleration Accounts 2027?
UK research organisations in the MRC remit (biomedical and life sciences); consortia from multiple institutions are permitted where scientifically justified.
What counts as activities within the MRC remit?
At least 50% of project spend must fall within MRC's remit; engagement and training activities are separately capped at 15% of the total budget.
Can I apply as a consortium?
Yes, consortia are welcomed; all institutions must be based in the UK and the lead institution submits via the UKRI Funding Service, with co-leads listed as project partners.
What is the deadline for the UKRI Translation Impact Acceleration Accounts 2027?
15 September 2026 at 4:00pm UK time, submitted via the UKRI Funding Service.
Summary generated by AI based on published grant information. Always verify details on the funder's website.
More from Medical Research Council (MRC)
Browse all open grants →Browse Related
Does this grant match your research?
Sign up free to get a personalised match score and weekly alerts for grants like this.
Get started free